Defitelio launches in Europe

|By:, SA News Editor

Jazz Pharmaceuticals (JAZZ +3.5%) and its recent acquisition Gentium launch Defitelio (defibrotide) in Germany and Austria.

The rollout will continue in 27 additional European countries in 2014 and 2015.

Defitelio is the first licensed product for severe hepatic veno-occlusive disease in patients over one month of age undergoing haematopoietic stem cell transplantation therapy.

The European Commission approved the product in October.

Consensus Q1 and Q2 estimates are earnings of $1.91 on revenues of $259M and $1.97 on revenues of $276.3M, respectively.

Consensus estimates for 2014 and 2015 are earnings of $8.21 on revenues of $1.14B and $10.16 on revenues of $1.36B, respectively.

574 mutual funds have positions, up from 448 a year earlier.